Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:1.16.3.1 (ceruloplasmin)
 5,074 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The metabolic effects of a new oral contraceptive Femodene (SHD 356C) containing 75 micrograms gestodene (delta-15-levonorgestrel) and 30 micrograms ethinyloestradiol were studied in two groups of women. Group 1 consisted of women not currently using oral contraceptives; Group 2 consisted of women switching to Femodene from their current oral contraceptive. Changes in lipid metabolism were assessed by measuring serum levels of cholesterol, triglycerides, LDL-C, VLDL-C, HDL-C, HDL2-C and HDL3-C. Minimal changes occurred in lipid metabolism apart from increases in triglyceride concentrations. Women in Group 1 showed a 105% increase in SHBG levels and a 51% increase in caeruloplasmin levels compared to increases of 33% and 2% in women in Group 2. A comparison of the two groups of women suggested that the gestagen in Femodene exerted a less anti-oestrogenic effect than most of the gestagens currently used in oral contraceptives. No significant changes occurred in liver function (assessed by estimation of gamma-glutamyl transferase) or in the coagulation factors, Factor X and antithrombin III. Minor effects on glucose tolerance as assessed by blood glucose and plasma insulin levels were noted. These minimal effects on metabolism, combined with its high efficacy and acceptability shown in clinical trials, makes Femodene an ideal alternative to currently used oral contraceptives.
 ...
PMID:Metabolic investigations with Femodene--an oral contraceptive containing gestodene and ethinyloestradiol. 288

As part of a study to determine the effect of 150 mg zinc/day on plasma lipoproteins, healthy young female (n = 26; mean age 27 years) and male (n = 21; mean age 28 years) volunteers took part in a double-blind cross-over trial lasting 12 weeks. During 6 weeks of supplementation, plasma Zn rose significantly in both groups, indicating compliance. Plasma total cholesterol remained unchanged in both males and females. However, mean LDL-cholesterol decreased from 2.38 to 2.17 mmol/l in females and there was a trend for total HDL-cholesterol to be redistributed in that HDL2 rose and HDL3 fell slightly. In parallel with these changes in females, Zn supplements reduced the ferroxidase activity of serum caeruloplasmin (from 13.0 to 11.3 U/ml) and the antioxidant activity of erythrocyte superoxide dismutase (E-SOD) (from 4557 to 3638 U/g Hb) and CuZn E-SOD (from 2184 to 1672 U/g Hb). Plasma Cu and haematocrit were unaffected. No such changes were seen in males in either lipoproteins or these indicators of Cu status. Since the females were lighter than the males but received the same dose, a dose-response effect rather than a sex difference cannot be ruled out. Overall, Zn supplements significantly decrease a major risk factor for CHD in females but reduced their Cu status.
 ...
PMID:The effect of zinc supplements on lipoproteins and copper status. 336 92

In an open-label, randomized, cross-over study in 20 subjects, the short-term effects were investigated of Gracial (DSG/EE 7 x 25/40 micrograms/day + 15 x 125/30 micrograms/day) and Trigynon (LNG/EE 6 x 50/30 micrograms/day + 5 x 75/40 micrograms/day + 10 x 125/30 micrograms/day) on plasma concentrations of 17 beta-estradiol and progesterone as well as on carrier proteins (SHBG, CBG, ceruloplasmin), AT-III, carbohydrate metabolism (insulin, glucose, glycosylated proteins) and lipid metabolism (total cholesterol, triglycerides, phospholipids, HDL-C, LDL-C, HDL2-C, HDL3-C, HDL2-C/HDL3-C ratio, Apo A1, Apo B, Apo A1/Apo B ratio). Both preparations adequately and similarly inhibited ovulation in all subjects. Serum levels of carrier proteins were significantly higher with DSG/EE than with LNG/EE, whereas no between-group differences were observed with respect to fasting glucose and insulin, glycosylated proteins (mainly glycosylated albumin) and AT-III activity. DSG/EE showed significantly higher plasma levels than LNG/EE of estrogen-dependent lipid parameters such as triglycerides, HDL-C, HDL2-C, Apo A1, HDL2-C/HDL3-C ratio and Apo A1/Apo B ratio, whereas the levels of LDL-C and Apo B were significantly lower. Both oral contraceptive preparations were equally effective in suppression of follicular development, but combiphasic DSG/EE induced higher plasma levels of carrier proteins and higher plasma levels of potentially anti-atherogenic lipid parameters than did triphasic LNG/EE.
 ...
PMID:A randomized cross-over study comparing pharmacodynamic and metabolic variables of a new combiphasic and a well-established triphasic oral contraceptive. 967 89